FibroGen, Inc. (KYNB)
NASDAQ · Healthcare
FibroGen, Inc. Shareholder Equity 2020–2025
FibroGen, Inc. annual shareholder equity history from 2020 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- FibroGen, Inc. shareholder equity as of December 31, 2025: 4.5M, a 102.44% decrease year-over-year.
- FibroGen, Inc. shareholder equity for 2025 were 4.5M, a 102.44% decrease from 2024.
- FibroGen, Inc. shareholder equity for 2024 were -183.6M, a 13.22% increase from 2023.
- FibroGen, Inc. shareholder equity for 2023 were -162.2M, a 10859.39% increase from 2022.
- FibroGen, Inc. shareholder equity for 2022 were -1.5M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| FibroGen, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $4 |
| 2024 | $-184 |
| 2023 | $-162 |
| 2022 | $-1 |
| 2021 | $229 |
| 2020 | $441 |
FibroGen, Inc. Shareholder Equity — FAQ
FibroGen, Inc. (KYNB) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see KYNB's shareholder equity history?
The chart and table above show FibroGen, Inc.'s shareholder equity by year and by quarter, including the growth rate.